ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
News|Articles|August 31, 2026
Midsized Biotechs Strike MFN Drug Pricing Deals
Author(s)Maggie L. Shaw
Fact checked by: Giuliana Grossi
This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.
Advertisement
Advertisement
Nine midsize pharmaceutical manufacturers have agreed to price outpatient drugs for state Medicaid programs in line with what they charge in other developed countries, the White House announced today,1 extending the administration’s Most Favored Nation (MFN) drug pricing campaign beyond the large drugmakers that have so far signed on to a tier of drugmakers that had largely sat outside these earlier deals.2
Related to this article
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Advertisement
Advertisement